The Clinical and Economic Impact of the Introduction of Emicizumab as Prophylactic Treatment for Hemophilia A Patients in Greece
Author(s)
Helen Pergantou, PhD1, Anna Kouraba, PhD2, Melina Arnold, MSc, PhD3, Georgia Kourlaba, PhD4, Alexis Crasaris, MSc5, Youli Kagkelari, MBA5.
1Aghia Sophia Children’s Hospital, Athens, Greece, 2Laiko General Hospital of Athens, Athens, Greece, 3F. Hoffmann- La Roche Ltd, Basel, Switzerland, 4Department of Nursing, Faculty of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece, 5F. Hoffmann- La Roche Ltd, Athens, Greece.
1Aghia Sophia Children’s Hospital, Athens, Greece, 2Laiko General Hospital of Athens, Athens, Greece, 3F. Hoffmann- La Roche Ltd, Basel, Switzerland, 4Department of Nursing, Faculty of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece, 5F. Hoffmann- La Roche Ltd, Athens, Greece.
OBJECTIVES: To evaluate the clinical and economic impact of the adoption of emicizumab as prophylactic treatment for patients in Greece with severe or moderate Hemophilia A (with or without inhibitors) and a severe bleeding phenotype.
METHODS: A treatment impact model was adapted to estimate the annual number of bleeds and associated direct medical costs over a 25-year horizon (2021-2046). Two scenarios were compared: one in which eligible patients have access to emicizumab, and one in which they do not. Annualized bleeding rates, hospitalization days, and utility values were sourced from international literature. Local epidemiological data, provided by two Greek healthcare professionals, were used to estimate the eligible population. Unit costs for bleed treatment, arthroplasty, and hospitalization were derived from official national sources and expressed in 2024 euros. Emicizumab market share projections were provided by Roche. Scenario analyses were also conducted to explore the impact of varying uptake levels over time.
RESULTS: Between 2021 and 2046, the introduction of emicizumab was projected to avert 109,506 treated bleeds (ranging from 12 in 2021 to 4,598 in 2046), resulting in a total reduction in direct medical costs of €735,967,270 (€120,637 in 2021 and €30,947,344 in 2046). The majority of savings with the introduction of emicizumab was attributed to decreased pharmaceutical costs for bleed treatment (€729,750,406 during the period 2021-2046). Scenario analyses demonstrated that the extent and speed of market uptake influence the magnitude of both clinical and economic benefit.
CONCLUSIONS: Emicizumab’s long-term adoption is expected to generate meaningful clinical improvements and substantial economic value for the Greek healthcare system. With an 86% projected reduction in direct medical costs by 2046, emicizumab represents a high-value investment for public health funding in Hemophilia A management.
METHODS: A treatment impact model was adapted to estimate the annual number of bleeds and associated direct medical costs over a 25-year horizon (2021-2046). Two scenarios were compared: one in which eligible patients have access to emicizumab, and one in which they do not. Annualized bleeding rates, hospitalization days, and utility values were sourced from international literature. Local epidemiological data, provided by two Greek healthcare professionals, were used to estimate the eligible population. Unit costs for bleed treatment, arthroplasty, and hospitalization were derived from official national sources and expressed in 2024 euros. Emicizumab market share projections were provided by Roche. Scenario analyses were also conducted to explore the impact of varying uptake levels over time.
RESULTS: Between 2021 and 2046, the introduction of emicizumab was projected to avert 109,506 treated bleeds (ranging from 12 in 2021 to 4,598 in 2046), resulting in a total reduction in direct medical costs of €735,967,270 (€120,637 in 2021 and €30,947,344 in 2046). The majority of savings with the introduction of emicizumab was attributed to decreased pharmaceutical costs for bleed treatment (€729,750,406 during the period 2021-2046). Scenario analyses demonstrated that the extent and speed of market uptake influence the magnitude of both clinical and economic benefit.
CONCLUSIONS: Emicizumab’s long-term adoption is expected to generate meaningful clinical improvements and substantial economic value for the Greek healthcare system. With an 86% projected reduction in direct medical costs by 2046, emicizumab represents a high-value investment for public health funding in Hemophilia A management.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO235
Topic
Clinical Outcomes, Economic Evaluation
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)